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WELCOME
This year’s Children’s Mercy Cancer Annual
Report focuses on the most common
sarcomas seen in children: osteosarcoma,
Ewing sarcoma and rhabdomyosarcoma.
Sarcomas are a diverse group of tumors
that still remain a significant challenge in
pediatric oncology.
Sarcomas occur in connective tissues, most
commonly the bones, muscles, tendons or
cartilage. While osteosarcoma occurs in
the bones, rhabdomyosarcoma occurs in
the soft tissues and muscles anywhere in
the body, and Ewing sarcoma can occur in
bone or soft tissues.
Curative therapy requires advanced
pathologic and genetic techniques, as
well as advanced radiologic scanning
to determine the extent of disease and
guide therapy. All of these tumors need
aggressive chemotherapy, which can take
up to a year to complete. During this time,
our patients can suffer infections and side
effects of chemotherapy, often requiring
the multidisciplinary subspecialty care
available at Children’s Mercy.

While chemotherapy is important, another
crucial factor in the ability to cure sarcomas
is “local control.” Local control refers to
the ability to control the primary tumor,
either by surgery or radiation. We work
closely with our surgical colleagues, both
at Children’s Mercy and at the University of
Kansas Cancer Center, to provide the best
surgical care and radiation oncology.
Once patients and their families make it
through the long road of chemotherapy
and local control, we enter a long
waiting process to monitor for disease
relapse and long-term side effects from
chemotherapy. Patients usually need to
continue in extensive physical therapy and
rehabilitation, depending on the location of
their tumor.
This year’s annual report illustrates
the breadth and depth of clinical care,
diagnostic capabilities, research and
psychosocial supports we provide at
Children’s Mercy. Today, a child with
sarcoma has a much greater chance of
cure than was possible 20 or 30 years ago,
but we still have a long way to go to be
able to cure every child.

Alan S. Gamis, MD, MPH
Associate Division Director, Section of Oncology;
Professor of Pediatrics,
University of Missouri-Kansas City School of Medicine

This has been an exciting year for the
Children’s Mercy Cancer Center as it adds
to its National Cancer Institute activity
with Children’s Oncology Group the new
designation as an NCI-designated cancer
center by virtue of its new consortium
status with the University of Kansas Cancer
Center. Research leading to current and
future improvements in cancer care are
a cornerstone of this designation. We
present a small part of that research in
this year’s annual report. As the new
Children’s Research Institute embarks on
the construction of its nine-story research
building, this is just a small taste of what is
to come in childhood cancer research here
in Kansas City.
Thank you to our donors and volunteers
whose philanthropic support sustains our
work, and to the staff at Children’s Mercy
who tirelessly works to support our patients
and their families. And thank you most of
all to the patients and their families who
allow us to care for them and guide them
through this difficult journey.

Katherine M. Chastain, MD
Bone and Soft Tissue Program Director;
Assistant Professor of Pediatrics,
University of Missouri-Kansas City School of Medicine

CANCER REGISTRY
The Cancer Registry at Children’s Mercy Kansas City plays a vital part
in the surveillance of cancer in our pediatric population. The Cancer
Registry is a HIPAA-compliant confidential database comprised
of malignant cancers, benign brain tumors and other specified
benign tumors. The database is operated under the guidance of the
Cancer Care Committee. Data collected, which includes diagnosis,
treatment, recurrence and survival, is standardized for state and
national comparisons.
Following each patient’s cancer status is a very important part of
Cancer Registry data collection. Knowing outcomes of each cancer
patient can assist with determining best treatment methods and
long-term effects of cancer treatment. Therefore, follow-up letters
inquiring about a patient’s cancer status are sent out yearly.
Parents and older patients are encouraged to contact the registry
by secure email at cancerregistry@cmh.edu to discuss follow-up.
During 2016, the Cancer Registry added 218
patients to the database. Of these, there
were 193 patients who were diagnosed with
malignancies and benign central nervous system
tumors. There were 25 patients added to the registry
as having benign reportable conditions treated by
cancer specialists and surgeons. These conditions are
collected at the request of the Cancer Care Committee for
surveillance purposes and are not required to be reported
outside our facility.

Patients from 26
Missouri counties

KANSAS
Patients from 27 Kansas counties

MISSOURI
Patients from 1 Arkansas county

OKLAHOMA
Patients from 2 Oklahoma counties

ARKANSAS

TEXAS

Patients from 2 Texas counties

Geographic
Locations of
Oncology Patients at
Children’s Mercy - 2016
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Sarcoma Diagnoses by Age
2006-2016
1

21+ YRS
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20
43.59%
11-20 YRS
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0-10 YRS

118

15
25.64%
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SARCOMAS

Sarcomas are rare but aggressive cancers that arise
from cells of mesenchymal origin. These malignant
tumors can arise from bone, cartilage, fat, muscle or
vascular tissues. These cancers require an experienced
multidisciplinary medical team of pediatric oncologists,
surgeons (including general surgery, urology, ear nose
and throat, and orthopaedic oncology) to adequately
care for them.
While there have been significant improvements in
all childhood cancer treatments since the 1970s, with
childhood cancer mortality dropping by more than 50
percent since 1975, pediatric sarcomas remain a difficult
group of cancers to treat.
Children’s Mercy Kansas City sees about 20 new patients
on average each year with sarcomas. The survival data
is closely compared to national statistics to ensure stateof-the-art care.
General information and updates on the three most
common types of bone and soft tissue sarcomas seen
in pediatrics follows.

OSTEOSARCOMA
Osteosarcoma is the most common bone tumor in
children and adolescents, with approximately 450 cases
in pediatrics and young adults in the United States per
year. Osteosarcoma presents with pain and swelling
around the tumor and often a limp if the tumor is in
the lower extremities. Osteosarcoma most often occurs
in the long bones around the knee, but can occur
anywhere in the body. The diagnosis of osteosarcoma
is made via biopsy. It is important that an experienced
orthopaedic surgeon performs the biopsy, as this
procedure is performed with the future resection in mind,
and misplaced biopsies can compromise future local
control.

methotrexate. Local control with surgery is crucial to a
good outcome in osteosarcoma, as osteosarcoma is
not sensitive to radiation therapy. Most patients with
osteosarcoma will be good candidates for a limbsparing approach. While amputation is uncommon,
it is still necessary in some cases. Many options exist
for custom prostheses in children, including magnetic
expandable prostheses that allow for continued growth
of the child.
The survival rate for localized osteosarcoma has
improved from early studies to an overall survival rate
of 65 percent at five years. About 20 percent of patients
have metastatic disease at diagnosis, and the overall
survival for these patients is approximately 30 percent at
five years, although this is dependent on the location and
the ability to resect metastatic sites. Efforts to intensify
therapy for patients with poor prognosis have not
improved survival. An international cooperative group
trial intensified therapy for those with a poor response
to upfront chemotherapy with the addition of ifosfamide
and etoposide. This did not result in increased event-free
survival or overall survival. Newer agents are in continual
development for use in large cooperative trials.

Poor prognostic factors for osteosarcoma include a large
size primary tumor, primary tumor sites in difficult-toresect locations, and the presence of metastatic lesions
in the lungs or other bones. After the administration of
induction cycles of chemotherapy, the degree of tumor
necrosis (less necrosis being unfavorable), and positive
margins at the time of primary tumor resection are also
poor prognostic factors.
Treatment of osteosarcoma requires aggressive
chemotherapy with cisplatin, doxorubicin and

Osteosarcoma Overall Survival
Kaplan - Meier

100

91.67%,
13.17 Months

97.22%,
9.33 Months

90
80

Percent Surviving

70

60.32%,
60 Months

67.65%,
38.7
Months

60
50
40
30
20
10
0

OSTEOSARCOMA OS (N=39)
0

10

20

30

Months After Diagnosis

8

40

50

60

KAMBRE KONRADE
OSTEOSARCOMA

KAMBRE KONRADE
The first day of kindergarten is one many parents remember—as both a happy and sad
milestone. But Kambre Jo Konrade’s first day marked a milestone of a different kind. She was
diagnosed with osteosarcoma—bone cancer.
That afternoon, the 5-year-old took a tumble off the
monkey bars at school in Spearville, Kan., a small
town northeast of Dodge City. During the evening, she
complained that her leg still hurt. A trip to the ER led
to an X-ray that initially seemed reassuring: no breaks
or fractures. But the radiologist saw a grapefruit-sized
mass above Kambre’s knee and forwarded the image to
doctors in Wichita, Kan., and Kansas City. They confirmed
the Dodge City doctors’ suspicions: tumor.

remove the lower section
of the leg and reattach the
ankle and foot backwards
to the thighbone. The ankle
then acts as a knee joint for
a prosthesis.
Dr. Chastain said, “Ensuring
that rotationplasty was the
best choice for Kambre
was important, because
we had to balance getting
out a large tumor in a small
child, plus making sure
she had good function and
no limitation in what she
wanted to do going forward.”

Kambre was referred to Children’s Mercy Kansas City for
assessment and treatment. Her oncologist, Katherine
M. Chastain, MD, Assistant Professor of Pediatrics,
remembered how—early on—she was impressed with
Kambre’s resilience.
“I could not believe this little girl had this huge tumor and
very little pain,” Dr. Chastain said. “Just goes to show
how tough she is!”

Kambre and her mom arrive
for an appointment.

Kambre proved immediately after surgery that “good
function” would be an understatement in her recovery.
The same day as the procedure, for example, she could
move her toes on command.

That toughness would be critical in facing her illness.
Kambre was “too small with too many years left to
grow,” her mother, Morgan, explained. That meant
doctors couldn’t follow the typical procedure of removing
the cancerous bone and installing an expandable rod.

“Normally that takes about two-plus days,” Morgan
explained. “Kambre could also move her foot back and
forth!” Later, on her first attempt with her prosthesis,
Morgan said, “She did unbelievably well. It’s like she
knew no different. Amazing is just what she does and
who she is!”

“They didn’t make a rod small enough to fit her little leg
nor with the potential to expand as much as she still
could grow.” In addition, a specific margin of healthy
bone must be removed to ensure all the cancer is
eliminated—a critical necessity because recurrence
yields less than a 30 percent survival rate. Plus, the
typical procedure would have required additional major
surgeries throughout Kambre’s life.

The same could be said about the Children’s Mercy staff.
“Children’s Mercy and all the providers we encountered
along the way have been incredible,” Morgan said.
“The specialty knowledge of her illness and willingness
of her providers to listen to us and support us, as well
as educate us, made us confident we were in the right
place. Children’s Mercy knows kids and addressed the
needs not only of the illness, but emotional, physical and
mental, as well. We loved the family we became a part
of while there!”

“The risks offset
the benefits
substantially,”
Morgan said.
Yet, the safer
surgery for
Kambre
was also an
extreme one:
rotationplasty,
a procedure
in which
surgeons

Kambre will continue to be part of that family for many
years to come. “She has a good prognosis,” explained
Dr. Chastain. “But osteosarcoma can still come back. So
we will follow her a long time with regular scans.”
Morgan added, “While you expect good care in a
hospital, we continue to be humbled and beyond
thankful for the nurses and doctors at Children’s Mercy.”

Lindsey Fricke, APRN, and Dr. Chastain strike
a pose with Kambre during a recent visit.
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EWING SARCOMA
Ewing sarcoma is the second most common bone
tumor in children. It often presents in bones similar to
osteosarcoma, but can also present in the soft tissues
anywhere in the body. Ewing sarcoma most often
presents with pain and swelling around the site of the
tumor, and often is misdiagnosed for quite some time
due to vague pain and the rarity of the tumor. Fever and
weight loss can also occur.

Chemotherapy uses five drugs (vincristine, doxorubicin,
cyclophosphamide, ifosfamide and etoposide), in
compressed cycles every two weeks. Local control
of the primary tumor is also crucial, and can involve
surgery or radiation therapy. Surgery is the preferred
method of local control if the tumor can be resected
with negative margins. If surgery is performed, the
tumor will be examined for necrosis, which corresponds
with the effectiveness of chemotherapy. Patients with a
high percentage of residual viable tumor have a worse
outcome than those with a large amount of necrosis.

Ewing sarcoma is diagnosed by biopsy, and there are
several characteristic features of Ewing sarcoma that aid
in diagnosis. First, Ewing sarcoma belongs to a group of
“small round blue cell tumors” due to its characteristic
appearance. CD99, a surface membrane protein, is
expressed in most cases of Ewing sarcoma. There are
also characteristic translocations involving the EWSR1
gene on chromosome 22. Most commonly this partners
with the FLI1 gene on chromosome 11; however, other
partners have been described.

Recent cooperative group trials showed improved
survival when using compressed cycles (every two
weeks) instead of traditional three-week cycles. Ongoing
studies are looking at additional agents to the standard
five-drug regimen in both localized and metastatic Ewing
sarcoma to further improve survival.
In Ewing sarcoma the five-year survival rate has
increased to 78 percent for localized tumors thanks to
cooperative group studies. Metastatic disease is present
in 25 percent of patients at diagnosis, and survival in
metastatic disease is still poor with an event-free survival
of approximately 28 percent.

Treatment for Ewing sarcoma involves intensive
chemotherapy, surgery and/or radiation. Even if there
is not metastatic disease seen on scans, we know
that there is occult metastatic disease too small to be
visualized with current imaging techniques. Therefore,
chemotherapy is paramount to cure.

Ewing Sarcoma Overall Survival
Kaplan - Meier
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ALEXANDER GOODWIN
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ALEXANDER GOODWIN
Maruska and Jeff Goodwin weren’t initially worried when their usually happy, precocious,
8-year-old son complained about pain in his leg. But then it began waking him at night
and their parental instincts went on high alert. When Alex began limping and was in nearly
constant discomfort, the Leicester, United Kingdom, couple went searching for help.
For seven months, they took their son from one doctor to
another, from Leicester to Sheffield to Birmingham, but
there was no definitive diagnosis.

very well-informed
of every step taken,
something we
weren’t used to in the
U.K.”

Meanwhile, Alex’s health worsened. “He was rapidly
losing weight, was always very tired, stopped attending
school, stopped eating and was in constant, unbearable
pain,” his mother said.

In January 2017,
surgeons in Kansas
City removed Alex’s
tumor and thigh
bone. He received
titanium versions of
his femur and knee
cap, followed by
more chemotherapy
and a unique
radiation treatment.
By July, his cancer was gone. That same month, doctors
replaced his titanium femur with a telescopic version that
could grow with him.

Finally, doctors re-evaluated the boy’s condition and
referred him to a bone-tumor specialist. A biopsy
confirmed what the parents had feared all along:
cancer—specifically, Ewing sarcoma. Tests showed a
tumor had destroyed Alex’s right hip and thigh bone.
Alex eventually began chemotherapy, but by then his
health had significantly deteriorated. Soon, doctors
told his parents nothing else could be done. Surgery to
remove the tumor would simply reduce the quality of
time Alex had left. His mother and father should prepare
to say goodbye to their little boy.
But Alex’s parents chose a different path, beginning with
an online search for help. Their efforts led them “across
the pond” to Children’s Mercy. And doctors here offered
a much different perspective on the little boy’s illness.

Alex headed home in August, but he’ll be returning
every three months for the first year, and then continued
follow-up for many years to come. Dr. Chastain will
check regularly to ensure his cancer hasn’t recurred, and
his telescopic femur will be incrementally extended.

In December 2016—11 months after initially seeking
treatment for their son—the family flew to Kansas City.
After reviewing his records, Katherine M. Chastain,
MD, oncologist and Assistant Professor of Pediatrics,
University of Missouri-Kansas City, said the team here
could offer surgery and further treatment. “We wanted to
give some hope that we could help,” she said.

“Alex’s case has been challenging because of the
aggressiveness of his tumor and the extensive surgery
he required,” Dr. Chastain said. “But he has done
remarkably well.”
His parents see the
same fortitude. Maruska
said, “Alexander is
getting stronger every
day. We will forever be
grateful not only to the
medical professionals,
but to the numerous
friends we made.
Kansas City will always
feel like a second home.

Alex was immediately admitted to Children’s Mercy,
and chemotherapy was restarted as the health experts
assessed
his
condition.
“His
treatment
was very
efficient,”
Maruska
said. “We
felt we were

“The level of expertise
and care we received was astounding,” she added. “We
feel so fortunate to have come here.”

Alex with his “Mum” Maruska.
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RHABDOMYOSARCOMA
Rhabdomyosarcoma is a highly aggressive malignant
tumor of mesenchymal origin. It often is associated with
skeletal muscle, but can occur in locations that lack
skeletal muscle, making the cell of origin elusive. It is the
most common soft tissue tumor in children, although it
is still overall a rare malignancy with approximately 350
cases in the United States per year. Rhabdomyosarcoma
occurs in two distinct subtypes; embryonal RMS, and
alveolar RMS. ERMS is the more common subtype and
has a better prognosis than the alveolar subtype. The
alveolar subtype occurs in approximately 25 percent of
cases, and is often associated with FOXO1 translocations.
Tumors that appear to be alveolar, but lack the
characteristic translocation, have outcomes equivalent to
those with the embryonal subtype.

Rhabdomyosarcoma is usually curable in most children
with localized disease, with more than 70 percent overall
survival for those in low and intermediate risk categories.
Metastatic disease continues to be a challenge to cure,
especially in those with alveolar rhabdomyosarcoma.
Pediatric sarcomas have seen great advances in survival
in the last several decades, but there is considerable
work yet to be done to improve survival, especially for
those with metastatic disease. As we work to improve
outcomes, we also strive to prevent side effects from
the therapy we give. Survivors of childhood cancer may
have therapy-related sequelae, including ototoxicity,
cardiac toxicity, radiation side effects, and issues with
prostheses. It is imperative that these children be
followed in a long-term survivorship clinic such as the
Children’s Mercy Survive and Thrive Clinic, to screen for
late effects. Early detection can minimize complications
and improve quality of life. Now with more and more
children surviving their cancer and living into adulthood,
transitioning to adult providers knowledgeable in these
sequelae is increasingly critical to prevent or reduce later
health complications. The combined program developed
with the University of Kansas Cancer Center offers a
seamless transition for our patients as they become
adults.

Rhabdomyosarcoma is treated with chemotherapy and
local control with surgery or radiation. Radiation is often
preferred over surgery in rhabdomyosarcoma, as tumors
in the head and neck or genitourinary system can be
difficult to completely resect. Chemotherapy varies by risk
group, but always includes a VAC backbone (vincristine,
dactinomycin and cyclophosphamide). Staging is
complex and factors in the location or tumor, subtype
(ARMS vs ERMS), size, metastasis and extent of the
surgical resection.

Rhabdomyosarcoma Overall Survival
Kaplan - Meier
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PERSEPHONE DURAN
RHABDOMYOSARCOMA

PERSEPHONE CONSUELA (SUELA) DURAN
Persephone Consuela (Suela) Duran had a better chance of being hit by lightning than
developing rhabdomyosarcoma.
Suela was a 12-year-old when she began experiencing
what seemed to be harmless, though uncomfortable
symptoms.

That specialized care included six months of weekly
chemotherapy treatments. So, every Friday, as soon as
Suela’s father, Johnny, got off work from his night shift at
the local college, the family packed into the car for the
175-mile drive from Salina to Children’s Mercy. Claudia
said the disease impacted her daughter’s life in many
ways.

Claudia, Suela’s mother, said frequent doctor visits
became the norm when Suela began menstruating. “We
knew something was wrong, because Suela’s periods
were extremely heavy, and she was always cramping,”
Claudia explained.

“She was
sick and
missed out
on sports,
visiting and
enjoying
her friends,
and eating
out. She
had to wear
a mask
to school.
Fevers were
a concern,
Suela is surrounded by the love of her parents.
and she
was sick to
her stomach on Mondays after treatment and couldn’t
attend school,” Claudia explained.

Suela’s pediatrician in her hometown of Salina, Kan.,
tried birth control pills and injections to lessen her
symptoms. Blood tests and physical exams initially
showed no cause. But, in early September 2013, a mass
was discovered in Suela’s uterus. She was 15 years old.
Surgery at the Salina Regional Health Center removed
the tumor, and it was sent for a pathology test. A
week later, results confirmed the teen had embryonal
rhabdomyosarcoma (ERMS). The protocol was for a
hysterectomy and chemotherapy.
Rhabdomyosarcoma is a rare cancer; just four per
million patients develop it before age 15. And, on
average, only 350 cases occur in the United States each
year in children under age 21.
Her parents were caught off-guard by the severity of
Suela’s illness. She had been a healthy child, taking
dance lessons and playing soccer over the years. “We
weren’t prepared for our 15-year-old to have her uterus
removed, a port put in and chemo for six months,”
Claudia said. “We were scared and devastated.”

But the staff at Children’s Mercy sustained them through
the fear and uncertainty. “Her treatment at Children’s
Mercy was the best you could hope for and receive,”
Claudia said.
Suela said Dr. Chastain was particularly reassuring when
the teen had questions. “She made me feel at ease with
her laughter and reassured me I would make it through,”
Suela said. “I felt like she cared about the whole person.
She let me know I would make it to college, and I did.”

While Suela’s chances of
getting the cancer may
seem unlucky, she had the
good fortune to live less
than 200 miles from one of
the premier hospitals in the
nation known for treating
the deadly disease.

Now a sophomore at Kansas State University, Suela is
studying business and hopes to become a veterinarian.
Dr. Chastain said her former patient had an excellent
chance of achieving that dream.

The staff at Children’s
Mercy was overwhelming
in its support, Claudia
added, especially
Katherine M. Chastain, MD, Assistant Professor of
Pediatrics, University of Missouri-Kansas City. When she
saw Suela’s test results, Dr. Chastain said, “I knew we
needed to get her specialized care.”

“She has a very good prognosis,” Dr. Chastain said.
“She’s already several years out with no signs of disease
recurrence.”
Claudia said she knew her daughter got “the best
medical care in the world,” adding, “Our child is alive
and well today because of Children’s Mercy staff.”
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DIAGNOSTIC
AND TREATMENT
SUPPORT SERVICES

PATHOLOGY OF SARCOMAS
Sarcomas are malignant tumors that arise from bone,
blood vessels, cartilage, fat, muscle or other connective
tissue. Although they are considered rare in general,
they are occasionally seen in the pediatric population.
They are many different types of sarcomas that originate
from bone or soft tissue and can arise anywhere in the
body, including visceral organs and the brain.

resemblance to cell of origin, estimate the density of
tumor cells, identify bizarre-looking pleomorphic cells,
count the number of cells in mitosis, and identify areas
of necrosis. Histologic examination is also helpful to
identify invasion of the tumor cells into blood vessels
or extension outside the organ of origin. Pathologic
examination can also confirm metastasis, i.e., seeding
of tumor cells in the lymph nodes, lungs or other distant
sites.

When pathologists receive a tumor specimen, they
examine the tumor under the microscope, identify the
type of sarcoma and determine its grade and extension
into the body organs. Sarcomas are named according
to the tissue of origin they resemble, e.g., a malignant
tumor that resembles bone or where the cells are trying
to produce bone is called osteosarcoma. The most
common sarcomas in children are rhabdomyosarcoma
(arising from skeletal muscle), osteosarcoma (from
bone), and Ewing sarcoma (can arise from either bone or
soft tissue).

Sometimes the pathologist will have difficulty in
determining the type of the tumor or in differentiating
one sarcoma from the other. In these situations,
additional studies are performed to determine the
type of protein or DNA molecules the tumor cells
are secreting. Identifying protein expression through
immunohistochemical techniques is a common way
to confirm the identity of the tumor. Molecular studies
are also performed to identify genetic events that are
characteristic for each type of sarcoma. The results
of all the macroscopic and microscopic examination,
immunohistochemistry and molecular tests (if available)
are combined into a comprehensive pathology report
that is sent out to the treating physicians and patients.
To maintain quality of pathology operations, the tumor is
frequently examined by more than one pathologist.

Infantile fibrosarcoma occurs mainly in infants and young
children. Rhabdomyosarcoma and Ewing sarcoma are
considered high grade and can significantly affect the
patient’s survival. Other sarcomas can be labeled as
low, intermediate or high grade based on certain cellular
characteristics. To determine the grade of the tumor,
the pathologist has to determine the degree of tumor

Rhabdomyosarcoma tumor cells trying to resemble
or differentiate into skeletal muscle cells.
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SURGERY

RADIOLOGY

Over the last several decades, there have been
remarkable advances in the surgical management of
sarcomas. While some sarcomas can be treated with
radiation, others require complete resection in order to
achieve a cure. Resection of large tumors in a growing
child or adolescent is extremely complex. When a child
is diagnosed with a bone or soft tissue sarcoma, it is
imperative that they have a specialized orthopaedic
oncologist who is familiar with the unique problems that
arise in children.

The prognosis and management of sarcomas has made
great strides in the past 20-plus years, thanks in part to
the enhanced role of Radiology in the team management
of these complex patients
Radiology is part of the multidisciplinary team for
sarcoma patients. Interpretation of imaging by the
diagnostic radiologist is essential for initial staging,
therapy planning, and long-term surveillance. The
interventional radiologist can provide a minimally
invasive method of lesion sampling as part of the
diagnostic work-up and follow-up. In some cases,
Radiology provides a treatment arm as well, utilizing
image-guided tumor ablation or embolization techniques
to augment traditional treatment methods.

Orthopaedic oncologists provide a specialized approach
to remove tumors and reconstruct the bones to allow
for normal function and full mobility. Orthopaedic
oncologists have done extensive training beyond
a general
orthopaedics
residency, and are
familiar with the
unique needs of
sarcoma patients.
Bone tumors in
children most
commonly occur
close to the growth
plates, which then
must be excised
during their definitive surgery. This can result in severely
impaired growth of that extremity. Resection of sarcomas
in children requires thoughtful planning and innovative
surgical techniques as they continue to grow to their
adult height and to maximize their function.

PHYSICAL THERAPY
Physical therapy plays a significant role as part of the
multidisciplinary team to promote optimal recovery and
return of function in children with sarcomas. Physical
therapists work to develop individualized exercise
programs that combine stretching and resistance
exercises to help reduce fatigue, as well as improve
mobility, safety and overall function. Physical therapy
is very important after limb salvage procedures and
amputation surgeries, working on post-surgical mobility
training, strengthening, endurance restoration, pain
management and education. Often, children will have
activity restrictions after surgery including weight bearing
precautions. Physical therapy teaches children how
to maintain these precautions with use of assistive
devices including walkers, crutches and canes. Physical
therapy allows patients to learn how to use a new
prosthesis correctly and in a safe environment, as well as
promoting optimal limb function. Physical therapy may
also recommend bracing or splinting to assist with range
of motion, muscle weakness and function.

The goal of surgery is to always completely remove
the sarcoma. In the past, amputation was the most
common option. However, with advances in prostheses
for children, amputation is now a last resort. Our team
commonly uses a non-invasive magnetic expandable
prosthesis. This prosthesis contains a powerful magnet
that can be activated to lengthen the prosthesis. This
allows for growth, without the needs for repeated
invasive surgeries.
Howard Rosenthal, MD, and the orthopaedic oncology
team at the University of Kansas Sarcoma Center work
closely with the medical Sarcoma Team at Children’s
Mercy, as well as radiation oncology to provide a
multidisciplinary approach to optimize care for pediatric
patients with sarcomas.
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SURVIVE & THRIVE
The Survive & Thrive Program began in 2009 and offers
comprehensive medical and emotional care to childhood
cancer survivors who are at least two years off treatment
and five years from the date of diagnosis. The program
began with a monthly clinic and has grown to four clinics
per month with more than 250 survivors receiving care.

cardiologists during cancer treatment and after for
survivors. Monitoring for and addressing cardiac
concerns early can reduce the risk of severe or lifethreatening heart problems. Examples of heart problems
that may arise during and after cancer treatment include:
heart failure, valvular heart disease, left ventricular
function, elevated cholesterol, elevated blood pressure
and arrhythmia. The collaboration with the pediatric
cardiologists ensures survivors at risk for cardiac
problems receive comprehensive screening, education
and intervention as needed.

Childhood cancer survivors are at risk for health
problems or late effects from their cancer and treatment.
Late effects can be physical or emotional and typically
appear in the second decade of life. The development of
late effects may be influenced by the type of cancer, the
treatment, age at diagnosis and genetic predisposition.
An estimated 95 percent of childhood cancer survivors
will develop at least one late effect at some point during
their life. Late effects may be preventable or modifiable,
which is why lifelong follow-up is important for all
survivors.

A visit to the Survive & Thrive Clinic includes a thorough
physical exam, recommendations for long-term followup care, education on late effects of cancer treatment
and how to maintain a healthy lifestyle. Assessments
by a dietitian and social worker are included in the
survivorship clinic visit to ensure all needs of the survivor
are met. In conjunction with the hospital-wide Transition
to Adulthood Program, preparation for transition to adult
providers is incorporated into each visit once survivors
reach 15 years of age. The Survive & Thrive team works
with each survivor to teach skills to advocate for their
health care needs and develop an individualized
transition plan.

Examples of late effects include hearing loss, heart
dysfunction, infertility, organ dysfunction (i.e., restrictive
or obstructive lung disease), endocrine dysfunction and
development of a second cancer. In the Survive & Thrive
Clinic, survivors are monitored for development of late
effects according to the Children’s Oncology Group Longterm Follow-up Guidelines.

In addition to clinic, the Survive & Thrive team
participates in various activities to raise
awareness about the importance of
ongoing follow-up care for survivors.
The team participates in the
KC Cares Walk and Tour de
BBQ, and has also hosted
educational conferences for
survivors and their families.
Along with the Regional
Hemophilia Treatment Center,
the Survive & Thrive team hosts
the LAUNCH Transition Program
for adolescents, young adults
and their parents/caregivers. The
goal of this program is to
provide information and
resources to facilitate
smooth transitions not
only in health care,
but in other areas
of life (education,
career, money
management and
independent living).

The Survive & Thrive team ensures diagnostic tests and
labs are completed according to the guidelines and
referrals are made to other specialists when necessary.
The Survive & Thrive team works closely with health care
providers in other specialties to ensure each survivor’s
unique health needs are met. Specialists the team works
closely with include endocrinology, cardiology and
developmental and behavioral sciences.
In 2016, Children’s Mercy launched the Cardio-Oncology
Program to better meet the needs of cancer patients at
risk for developing cardiotoxicity (damage to the heart
and vascular system).
Anthracyclines are a class of chemotherapy drugs
used in many pediatric cancer treatment regimens.
Anthracyclines, even in low doses, increase the risk of
heart problems in cancer survivors. Radiation therapy
that involves the heart or major vessels (vena cava
and aorta) also increase the risk of developing heart
problems.
The Cardio-Oncology Program offers specialized
treatment that incorporates screenings by pediatric
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CYTOGENETICS
Laboratory methods used at Children’s Mercy include
gold standard conventional chromosome analysis,
fluorescence in-situ analysis, microarray analysis, and
select somatic mutation analysis. Chromosome analysis
visualizes the entire genome to detect gain or loss
and rearrangement of chromosomes. Microarray, a
high-resolution analysis of the chromosomes, detects
loss of heterozygosity, gain or loss, and unbalanced
rearrangement of chromosomes. FISH analysis assesses
the status of specific genes, while somatic mutation
analysis detects changes within genes. Each of these
technologies offers a different assessment of the tumor
and together provide the most complete picture of
the genetic changes that drive the tumor’s growth.
Knowledge of these genetic changes informs therapeutic
choices.

Laboratory analysis reveals unique genetic changes that
are present in every tumor. Findings provide information
to aid in diagnosis and subtyping of each tumor and
contributes information for therapeutic management. The
status of important genes is determined: fusion of two
genes in an abnormal way can cause cell growth; gain
of too many copies of a gene encourages cell growth,
while loss of certain genes takes away control of cell
growth.
Figures 1-3 demonstrate subtypes of rhabdomyosarcoma
and their genetic differences.

Fig 1. (above) Alveolar rhabdomyosarcoma (ARMS) is
characterized by gene fusions in ~80 percent of tumors. PAX3FOXO1 fusion, found in ~60 percent of ARMS, is shown by the
karyotype as a reciprocal translocation of material between
chromosome 2 long arm and chromosome 13 long arm. There
is gain of an extra copy of the abnormal chromosome 13.

Fig 2. (left) Alveolar rhabdomyosarcoma (ARMS) with a
PAX7-FOXO1 fusion is seen in ~20 percent of tumors. The
karyotype shows a reciprocal translocation of material
between chromosome 1 short arm and chromosome 13 long
arm, which results in the PAX7-FOXO1 fusion. The tumor has 91
chromosomes and two copies of the abnormal chromosome 1.

Fig 3. (left) Embryonal rhabdomyosarcoma (ERMS) commonly
shows a hyperdiploid karyotype without translocations or
gene fusions. This tumor has 59 chromosomes with gain of
extra copies of chromosomes 1q, 6, 7, 8, 12, 13, 19, 20, and 21.
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ADVANCED PRACTICE PROVIDER
The advanced practice provider is an integral member
of the team that manages and cares for patients
with a sarcoma diagnosis. The APP is responsible
for coordination and management of the patient’s
care within the team which includes the oncologist,
orthopaedic oncologist, radiation oncologist, registered
dietitian, physical and occupational therapists, social
worker and child life specialists. Within Oncology at
Children’s Mercy, the child has a primary oncologist,
outpatient advanced practice provider and social worker
from diagnosis until transition to the Survive & Thrive
program.

APP provides education about the specific sarcoma,
treatment plan and how that treatment, which includes
chemotherapy, surgery and/or radiation, will affect the
patient and their family. The APP also performs physical
examinations, orders laboratory and radiology tests,
prescribes medications and chemotherapy. Children’s
Mercy also has inpatient APPs that manage care while
patients are hospitalized for chemotherapy. These APPs
see the patients daily and manage the day-to-day
happenings while in the hospital. Together, the inpatient
and outpatient APPs work together, along with the other
members of the team to provide the best care possible
for these patients.

The APP is the go-to person for the patient and their
family throughout their treatment and follow-up. The

EXPERIMENTAL THERAPEUTICS
Although most children and adolescents diagnosed with sarcomas are cured with standard therapy, unfortunately
there are some who will relapse or who do not respond to treatment. As initial treatment often includes surgery and/or
radiation therapy along with intensive chemotherapy, children who are not cured are left with limited options.
Fortunately, scientific research is making great strides toward improving our understanding of cancer biology. This
increase in knowledge is being translated into innovative therapies that are improving the lives of patients with cancer.
Many of these new medications are designed to specifically target cancer cells or harness the power of the immune
system to help kill cancer cells.
The Experimental Therapeutics in Pediatric Cancer Program brings many of these new, exciting drugs to patients at
Children’s Mercy. For children with sarcomas that are not cured with initial therapy, there are a number of phase 1
and 2 research trials that provide access to the newest and most promising treatments. As members of the Children’s
Oncology Group (COG) and the Beat Childhood Cancer consortium, Children’s Mercy is part of truly groundbreaking
research, striving to transform the remarkable amount of new information about how cancer cells function at a
molecular level into new therapies.
The Experimental Therapeutics Team at Children’s Mercy includes four physicians, an advanced nurse practitioner, a
social worker and four outstanding clinical research coordinators. They work together to ensure that our patients are
getting the best new treatments in the safest way possible.

22

CANCER PREDISPOSITION CLINCS
AND GENOME CENTER
In some cases, pediatric sarcomas are associated
with inherited mutations in cancer-causing genes.
There are several genetic changes that are known to
increase the risk of sarcomas in children. These include
mutations of the TP53 gene, which causes Li Fraumeni
syndrome, the RB1 gene, which increases the
risk of osteosarcoma, and the APC gene, which
is associated with desmoid tumors, as well as
many other rare genetic changes. In each of
these conditions, the child may be otherwise
healthy prior to the discovery of the sarcoma. A
strong family history of cancer, unusual types of
cancer, multiple cancers in one person, or adultonset cancers in childhood can be clues that a
family cancer syndrome may be present. The
Center for Genomic Medicine at Children’s Mercy
has developed a specialized, comprehensive
DNA sequencing test to detect cancer-causing
mutations in patients and their relatives.
Our genetic counselor meets with families to
discuss the test results. At-risk patients are
followed in our Cancer Predisposition Clinic

for health surveillance and specialized testing. For
more information about the genetic testing or the
Cancer Predisposition Clinic, contact, the Division of
Hematology/Oncology/Bone Marrow Transplantation at
Children’s Mercy Kansas City.
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FaCT
Multidisciplinary care is integral to the overall outcomes and well-being of our patients.
Outside of medically directed care, patients and families have many other needs that are
addressed by our Family Care Team (FaCT). Regular FaCT rounds and collaboration ensures
that we meet all physical, developmental, emotional, educational and spiritual needs. The
Family Care Team is available to assist from point of diagnosis through the completion of
treatment and beyond for patients with sarcomas or any other cancer.

The Child Life team consists of child life specialists and a patient activity assistant who
is also the handler of the facility dog on staff who works on the inpatient unit. The team
works collaboratively to support the psychosocial and developmental needs of children
and families. Child life specialists are trained professionals who help children cope with the
stress and uncertainty of illness and hospitalization. Child life specialists work to ensure life
remains as normal as possible for children. Child life specialists explain and teach patients
about medical procedures, coping skills and other health care experiences. As advocates
of family-centered care, child life specialists work in partnership with the medical team to
meet the unique emotional, developmental and cultural needs of each child. Patient activity
coordinators provide play activities and facilitate positive and safe play environments. They
promote patient engagement in play programs, volunteer interactions and special events.

Clinical social workers are master’s level licensed professionals working as part of the primary
team to provide comprehensive and compassionate family-centered care. Social workers
understand that any change in the child’s health can alter a family’s life in many ways, and are
trained to provide a thorough assessment and address the ongoing needs of the patients and
families. Social workers can help with therapeutic support including adjustment to illness, crisis
intervention, development of coping skills, family concerns, end-of-life, and bereavement; care
planning including education on advance directives, school concerns, legal issues, transition to
adult care, and end-of-life concerns; and community/resource referrals to assist with financial
concerns, transportation and lodging needs, support and mental health referrals. Every patient
has an assigned clinical social worker who follows the patient and family through diagnosis,
treatment, relapse, survivorship or bereavement.

The Parent-to-Parent Program offers support and comfort to families through the use of
specially trained parent volunteers and a clinical social worker. There are many services
offered through the PTP program including parent volunteers available to share, listen
and support our current parents; two stocked parent rooms that offer weekly dinners,
breakfasts, therapeutic and educational activities and a safe place to unwind while a
child is an inpatient; “care bags” for families upon unexpected admissions to help ease
some burden of a hospital stay; and new parent journals. The Parent-to-Parent program
also offers an extensive bereavement follow-up program that supports families for
approximately 13 months after a child’s death. We have successfully introduced social
media into our bereavement follow-up program. PTP has worked closely with a number
of local organizations, as well as the Children’s Mercy Cancer Center Auxiliary, and has
established ongoing philanthropic support of the parent rooms to serve the increasing
needs of our inpatient families. The program was highlighted at the 2017 Association of
Pediatric Oncology Social Workers conference.
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FaCT
The Adolescent and Young Adult Program is designed to support patients receiving treatment
for cancer or blood disorders. The team of providers includes a clinical social worker and
child life specialist who work in collaboration with other disciplines toward the goal of
improving the quality of care for the AYA population. Recent accomplishments include
the development of a teen unit and teen room on the inpatient floor; a formalized
peer mentoring program; additional programming and education around fertility
preservation; and improvements to transitioning to adult care. Ongoing projects include
the Hematology/Oncology Teen Advisory Board; Teenapalooza events to promote peer
interaction; and education and support.

There are two dedicated psychologists to assist patients and families with coping with the diagnosis and treatment
of sarcoma and other cancers. They are available to meet with patients and their families, both while hospitalized
and when outpatients. In addition to clinical therapeutic services, the psychologists are also able to complete
neurocognitive evaluations to assess any impact of the cancer or the medical treatment on brain functioning and to
assist with school re-integration and planning.

The chaplains regularly provide spiritual and emotional support to patients
and families during the course of a child’s illness and beyond. Providing tailormade rituals for patients and families at the time of significant events like bone marrow
transplant is another way a chaplain provides support. At the request of the family, the
chaplain can contact a family’s own clergy person/spiritual leader. For families who live
outside of the Kansas City area, at the request of the family, the chaplain contacts a local
leader from the family’s faith tradition to provide additional support. The chaplain provides
education about the spiritual resources that are available within the hospital, such as the
activities in the Lisa Barth Chapel like Sunday worship, concerts and celebrations from
various faith traditions. The chaplain participates in team meetings. Providing support to the
staff is another important role of the chaplain.

Music therapy services are offered to patients and families at bedside
to address the specific needs of individual patients. Music interventions
are designed after an assessment of need and generally involve the use
of both live vocal and instrumental music, as well as technology. Goals
may include but are not limited to the reduction of pain or anxiety;
increased self-expression, movement, or relaxation; and the support of
developmental skills. Patients are encouraged to take an active role in
making music and learning how to use music as a helpful and fun tool.

An on-site school teacher works with patients primarily on the inpatient floor with some availability in clinic as needed
to assist with the challenge of keeping up with school work while a patient is undergoing treatment. Our school teacher
is able to communicate directly with the child’s school to get current assignments and also to advocate for the patient’s
needs once they return to the school setting.
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RESEARCH FOCUSES ON MORE EFFECTIVE
SARCOMA THERAPY
Medical specialists at Children’s Mercy do more than treat children’s illnesses. They also
research ways to make treatments as effective as possible. Among these are two physician
scientists leading this effort in pediatric sarcomas work at Children’s Mercy.
Katherine M. Chastain, MD, Pediatric Hematologist
Oncologist and Director of the Soft Tissue and Bone
Tumor Program, is studying how pediatric solid tumors
respond to treatment. “I want to better understand and
develop treatments for solid tumors and other rare tumor
types,” she said.

For both physician scientists’ studies, samples are
collected from consenting patients who participate to
help future patients. Dr. Chastain’s study takes cells from
the tumors at the time of their initial diagnostic biopsy/
resection.
“We then use a new way of growing the cells in the lab
and to test new treatments,” such as different drugs or
drug combinations, she explained. “We will also test the
tumor cells before and after treatments and see what
differences we can find. The child’s tissues will be stored
in a way that allows cells to grow and multiply,” she
added. These multiplying cells may give rise to cell lines,
which can be kept alive for many years and used for
multiple future studies.

Glenson Samuel, MD, Pediatric Hematologist Oncologist,
is attempting to determine whether pediatric sarcoma
cells release nanosized molecules, exosomes, into the
circulation. These molecules could be used as markers to
monitor pediatric sarcomas.
“Exosomes may contain characteristics that are similar
to their originating tumor,” Dr. Samuel explained. “Our
research will help us better understand how sarcomas
work and can be monitored throughout therapy.”

Dr. Samuel’s exosome study uses blood samples from
newly diagnosed and recurrent patients. Samples are
collected throughout therapy to correlate research
findings with standard methods of monitoring pediatric
sarcomas.

An aspect of this exosome research has led to a
partnership with the Genomic Medicine Center at
Children’s Mercy. Other research focuses on targeted
therapies for progressive or recurrent pediatric sarcomas
patients, specifically on the molecular mechanism by
which cells multiply.

Katherine M. Chastain, MD

Glenson Samuel, MD
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CHILDREN’S MERCY CANCER CENTER PROGRAMS
BONE AND SOFT TISSUE SARCOMA PROGRAM
Sarcoma accounts for about 15 percent of all childhood cancers. Each year, Children’s Mercy treats about 20 children
with new diagnoses of bone or soft tissue tumors. The Bone and Soft Tissue Sarcoma Program at Children’s Mercy is
led by Katherine M. Chastain, MD, who completed fellowship at Memorial Sloan-Kettering Cancer Center. The program
includes: Orthopaedic Surgery (Howard Rosenthal, MD), Radiation Oncology (Vickie Massey, MD), Rehabilitative
Medicine (Kimberly Hartman, MD), Pediatric Oncology, Pathology, Interventional Radiology and Radiology. Our goal
is to provide seamless care coordination with a multidisciplinary tumor board and enhanced collaborative research
across disciplines.
The Bone and Soft Tissue Clinic allows patients to receive all services on one campus. Commonly treated diagnoses
include osteosarcoma, Ewing Sarcoma, rhabdomyosarcoma and non-rhabdomyosarcoma soft tissue sarcoma.

LEUKEMIA AND LYMPHOMA
The Leukemia and Lymphoma Program includes experts in the diagnosis and management of hematologic
malignancies in children and young adults. The program is a collaborative effort dedicated to delivering state-ofthe-art clinical care and to generate innovative research. Members include faculty from the section of Oncology,
Hematopathology, Cytogenetics and the Genomic Medicine Center. Comprehensive patient care meetings occur
monthly. Cases are reviewed and research discussed. Members are actively involved in the development of clinical
trials for leukemia and lymphoma on a national and international level through the Children’s Oncology Group and
other clinical research consortiums.

NEURO-ONCOLOGY PROGRAM
The Children’s Mercy Cancer Center Neuro-Oncology Program is led by
Kevin Ginn, MD, with a primary focus of providing access to cuttingedge cancer therapy for children in the Kansas City region with brain
and spinal cord tumors. Central nervous system tumors remain one
of the leading causes of cancer-related death and morbidity. These
patients benefit from the individualized care plans developed by
multiple subspecialists available at Children’s Mercy. Our frequent
tumor board allows in-depth discussion regarding each patient,
ensuring proper planning for improved patient care. Our involvement in
national consortiums such as the Neuroblastoma and Medulloblastoma
Translational Research Consortium and the Children’s Oncology Group
allows us to provide enrollment on clinical trials for both new and
relapsed patients. Exciting research collaborations through the Midwest
Cancer Alliance Partners have resulted in funded research investigating new therapies for glioblastoma and atypical
teratoid rhabdoid tumor, which are two of the most devastating tumors in pediatrics. The goal of the Neuro-Oncology
Program continues to be comprehensive care and cutting-edge therapy provided close to home.

HISTIOCYTOSIS PROGRAM
The Histiocytosis Program provides a comprehensive setting for care of a rare disease. The experience and knowledge
of a pediatric hematologist/oncologist, J. Allyson Hays, MD, provides current and inclusive clinical care. The
Histiocytosis Program also collaborates with pediatric orthopaedic surgeons, endocrinologists, dermatologists and
pathologists familiar with the rare diseases of Langerhans cell histioctyosis, hemophagocytic lymphohistiocytosis, sinus
histiocytosis with massive lymphadenopathy/Rosai Dorfman, juvenile xanthogranulomatous disease and ErdheimChester disease.
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SPANISH LANGUAGE PROGRAM
The Spanish-speaking Hematology/Oncology Program’s primary
mission is to bridge the gap in health care disparities among
Hispanic patients and families with limited English proficiency. We are
dedicated to providing comprehensive medical care to our patients
with an emphasis on language-concordant medical services and an
understanding of socio-cultural differences toward illness and health
care. This clinic provides patients and families a full line of clinical
services in Spanish. This includes written educational materials,
medication calendars, medication lists and appointment schedules.
The clinical implications of care for Spanish-speaking patients
with childhood cancer are noted in published literature. Acute
lymphoblastic leukemia is one of the most curable childhood cancers
with an overall survival rate for Caucasian children of approximately
85 percent. The outcome for Hispanic children is approximately 75 percent. The exact reasons for this difference are
unknown. A few small studies have implicated genetic differences in the leukemia cells themselves. Others have
suggested language barriers and socio-cultural differences. We see our Spanish language program as a starting
place for important research that will seek to discover the reason for differences seen in this population. Through
our partnering with our clinical pharmacology and genomics programs, research into these differences has been
developed and launched, with the intent to partner with other centers that serve large numbers of Hispanic children,
including several children’s hospitals in Mexico. We also see this as a means to develop clinicians skilled in the care of
children whose primary language is not English.

ADOLESCENT AND YOUNG ADULT PROGRAM
The Adolescent and Young Adult Cancer Program was developed to improve outcomes by focusing on increasing
awareness of the unique needs of AYA patients, improving compliance with treatment regimens and follow-up care.
Addressing the psychosocial, educational and occupational needs of patients on and off treatment to improve overall
quality of life is also a major focus of the program. At Children’s Mercy, we offer patients in this age group access to
clinical trials through the Children’s Oncology Group. Members of the program are also available to discuss cases with
adult oncologists treating patients with pediatric cancer who due to age are unable to receive treatment at Children’s
Mercy. We will gladly help guide their therapy and provide psychosocial support to the families.

CHILDREN’S MERCY TUMOR BANK
The Children’s Mercy Tumor Bank is a resource to clinicians and scientists who study the biologic basis of cancer in
children. The biorepository consists of a collection of blood and tissue, donated by patients with cancer and cancerrelated diagnoses. Information about each patient’s disease and response to treatment are also stored within the
biorepository. The rights and privacy of participants in the biorepository are protected by a research protocol approved
by the Children’s Mercy Institutional Review Board. The biologic samples and clinical data are accessible to researchers
at Children’s Mercy, its partner institutions, and the greater scientific community.

CANCER GENOMICS
The Cancer Genomics Program is working to bring cutting-edge genomics research into everyday patient care. While
cancer cure rates at Children’s Mercy are excellent when compared with national averages, we are always striving
to improve. Genomic medicine studies are providing new clues into the causes of cancer and will help design better
treatments.
Genomics studies of cancer cells can give us critical information about the genes and pathways that are active inside
the tumor. The field of cancer genomics is brand new, but growing rapidly. Children’s Mercy is a worldwide leader in
genomic medicine and has received international recognition for our ability to provide whole genomic sequencing for
critically ill neonates within a few short days. The same technology can be used to provide genomics information to our
cancer patients quickly when it is needed to guide treatments.
Currently, the Cancer Genomics Program is enrolling patients in research studies of pediatric cancer. Our vision is to
bring genomic medicine to every cancer patient at Children’s Mercy. We work in partnership with the Children’s Mercy
Genomic Medicine Center.

28

LIVER TUMOR PROGRAM
The Liver Tumor Program includes oncology, hepatology, surgery and liver transplant services. The team works to give
comprehensive care to children with liver cancer. Every patient’s treatment plan is discussed with all of the disciplines.
The coordination of care begins prior to diagnosis and continues even after treatment has been completed.

IMMUNOTHERAPEUTICS PROGRAM
The Cancer Immunotherapeutics Program promotes innovative basic and translational investigation designed to
support and launch clinical trials targeting pediatric and adult malignancies. The program supports local investigatorinitiated cancer-directed cellular-therapeutics trials at Children’s Mercy and the University of Kansas Medical Center
and participates in pharmaceutical-company sponsored trials of cellular therapeutics and complex biologics. Children’s
Mercy is one of the initial U.S. cancer centers to study and now offer the ground-breaking chimeric antigen receptor T
(CAR-T) cell therapy for leukemia.

PATIENT AND FAMILY RESEARCH
The Patient and Family Research Program focuses on individual and family development, as well as issues that occur
across the treatment trajectory that could compromise individual and family well-being. This includes supportive
care, symptom management and psychosocial needs for all members of the family. The patient and family research
program works in conjunction with other programs across the hematology/oncology/BMT spectrum in collaboration to
promote positive patient and family outcomes.

EXPERIMENTAL THERAPEUTICS
The Experimental Therapeutics in Pediatric Cancer Program provides access for patients to new and innovative cancer
treatments, placing Kansas City at the heart of national and international research efforts that are impacting the lives
of children with cancer everywhere. We have 17 Phase I and II trials available for relapsed or refractory cancer. The
Experimental Therapeutics team includes four physicians, each with their own specific area of interest including solid
tumors, blood cancers, cancer genomics, clinical pharmacology and neuro-oncology. The team also includes a fulltime advanced practice nurse practitioner and four dedicated clinical research coordinators.
As the only pediatric tertiary care hospital in the region, Children’s Mercy
cares for the vast majority of children in the area diagnosed with cancer.
The number of children treated at our Cancer Center continues to rise,
with an average of over 200 new cancer diagnoses a year. Children’s
Mercy serves as the pediatric partner for the University of Kansas Cancer
Center’s National Cancer Institute. This relationship allows for increased
resources and access to clinical trials, bringing cutting-edge cancer therapy
to our patients. Children’s Mercy is an active member of the Children’s
Oncology Group, an international consortium that develops and operates
clinical trials in childhood cancer. We are also a member of the Beat
Childhood Cancer Consortium (formerly NMTRC–Neuroblastoma and
Medulloblastoma Translational Research Consortium). We partner with
pharmaceutical companies to run several industry-sponsored clinical trials
to make sure our patients have access to novel therapies. In addition, the
Experimental Therapeutics program has a Precision Medicine Research
Core that encompasses the research pillars of cancer genomics and clinical
pharmacology to develop locally developed trials in pediatric cancer.
In a given year, Experimental Therapeutics treats 15 to 20 children on our clinical trials. In addition to local and regional
patients from the Kansas City area, we receive a number of outside referrals from other centers including Wichita,
St. Louis, Oklahoma, Colorado, Iowa, Arkansas, Illinois and Texas. We are one of only a handful of centers currently
treating children with difficult-to-treat leukemia with CAR T-cells, a revolutionary new therapy that uses a patient’s own
immune system to kill cancer.
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